Chronic myeloid leukemia (CML) is characterized by the Philadelphia translocation that fuses
BCR sequences from chromosome 22 upstream of the ABL gene on chromosome 9. The …

The advent of the Bcr-Abl selective tyrosine kinase inhibitor imatinib mesylate (Glivec,
Gleevec, Novartis, East Hanover, NJ) has substantially changed the treatment landscape for …

… targeted therapies that block Bcr–Abl tyrosine kinase activity. Imatinib, the current first-line
therapy for … This review will discuss the use of targeted therapies in CML, particularly in the …

… of targeting a key … targeted therapies of CML using BCR-ABL kinase inhibitors, with a
focus on the importance of developing a targeted therapy of CML through identification of target …

… Chronic myeloid leukemia (CML) management changed dramatically with the
development of imatinib mesylate (IM), the first tyrosine kinase inhibitor targeting the BCR-ABL1 …

… chronic myeloid leukemia and the potential therapeutic impact of small molecule inhibitors
that target … growth or survival of the leukemic cells in patients with chronic myeloid leukemia. …

… BCR-ABL1 is the central therapeutic target in CML and the … into a paradigm for molecularly
targeted therapy. A wealth of … of targeted therapy for CML from a biological perspective. …

… The development of therapeutic agents targeting BCR-ABL has revolutionized the treatment
of chronic myeloid leukemia (CML). Imatinib has successfully allowed CML patients to re…

Patients with newly diagnosed chronic myeloid leukemia (CML) usually received as first-line
treatment a first- or second-generation tyrosine kinase inhibitor (TKI). Although initial …

… Chronic myeloid leukemia (… Chronic myeloid leukemia may be more difficult to differentiate
from other myeloproliferative or myelodysplastic syndromes. Patients with agnogenic myeloid …